While grain and oilseed prices stabilized in the second half of 2015, broader commodity markets declined in response to slowing economic growth in china, a strong u. Regarding forwardlooking statements in sanofis annual report on form 20f for. Regeneron pharmaceuticals annual reports united states. Research sponsored by sanofi and regeneron pharmaceuticals, inc. Medical writingeditorial assistance provided by jeanne dushane, phd, of excerpta medica, funded by sanofi genzyme and regeneron pharmaceuticals, inc. Sanofi and regeneron launch major new immunooncology. Sun pharmaceutical industries detailed director reports covering sun pharma financial results and performance report. It covers all regions and divisions from 1 january to 31 december 2018.
Inside regeneron pharmaceuticals incs 10k annual report. Exact name of registrant as specified in its charter. Filing year any 2020 2019 2018 2017 2016 2015 2014 20 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995. Regeneron is a leading sciencebased biopharmaceutical company based in. Regeneron pharmaceuticals balance sheet annual export data. Sanofi and regeneron present results from phase 3 monarch study of investigational sarilumab at american college of rheumatology annual meeting in. In depth view into regeneron pharmaceuticals revenue annual including historical data from 1991, charts, stats and industry comps. Please note, copies of all reports submitted by the company to the securities and exchange commission the sec, including any exhibits that may be part of these reports, can be retrieved under the sec filings link above. The sole purpose of this amendment is to amend exhibits 10. Regeneron reports fourth quarter and full year 2015 financial. Download annual report in pdf format 2018 2017 2016 2015 2014 20 2011. Regeneron reports fourth quarter and full year 2015. Regeneron pharmaceuticals incregn annual report 10k.
On 10 october 2019, ucb announced its intention to acquire ra pharma. If this is an annual report, indicate by check mark whether the. Statement of changes in beneficial ownership of securities. November 16, 2015 november 15, 2015 regeneron pharmaceuticals, inc. The interim condensed consolidated financial statements of regeneron pharmaceuticals, inc. Early drug development investor relations event 2019. Regeneron will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2017 financial and operating results on thursday, february 8, 2018, at 8. Financial expense highlight nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and are recognized as research and development expense as the related goods are delivered or the related services are performed. A phase 2b3 clinical study 16weeks in patients with pain due to. The company will provide, free of charge upon request, its annual report on form 10k which contains the companys complete audited financial statements. Regeneron reports fourth quarter and full year 2017 financial. In the second quarter of 2015, sanofi provided notice to regeneron that it had. These statements concern, among other things, the possible success and therapeutic applications of our product candidates.
Financial information regeneron pharmaceuticals inc. Sanofi and regeneron present results from phase 3 monarch. Regeneron reports fourth quarter and full year 2016 financial. Regeneron pharmaceuticals regn investor presentation. Regn sec filings, 10k, 8k regeneron pharmaceuticals, inc. If this is an annual report, indicate by check mark whether the registrant is a shell. Ninemonth 2019 sales presentation without appendix. Screenshot taken from wynns 2018 10k annual report member feature read positive and negative remarks made by management in their entirety without having to find them in a 10kq. Regeneron reports fourth quarter and full year 2015 financial and operating results form 10k. In 2015, total revenues earned by regeneron pharmaceuticals amounted to 4. View the latest regn financial statements, income statements and financial ratios. Jun 12, 2017 the following slide deck was published by regeneron pharmaceuticals, inc. Annual report which provides a comprehensive overview of the company for the past year.
Sun pharmaceutical industries directors report, sun pharma. European society for medical oncology esmo 2019 congress highlights from roche. Regn sec filing 10k annual report for the fiscal year ending tuesday, december 31, 2019. Annual reports and proxies alexion pharmaceuticals, inc. Materials on this website may contain information about the companys future plans and prospects that constitute forwardlooking statements for purposes of the safe harbor provisions under the private securities litigation reform act of 1995. Following the end of each calendar quarter, within fifteen 15 days after receipt by regeneron of the net sales report from aventis pursuant to section 9. Astrazeneca annual report and form 20f information 2016.
Regeneron or the company have been prepared in accordance with the instructions to form 10q and. Annual report on form 10k, which are available on the investor relations portion of our website. Originally focused on neurotrophic factors and their regenerative capabilities thus the name, it branched out into the study of both cytokine and tyrosine kinase receptors. A phase 3 study of eylea for the treatment of nonproliferative diabetic retinopathy in patients without diabetic macular edema dme was initiated in the. This annual report on form 10k contains forwardlooking statements that involve risks and. If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. Indicate by check mark whether the registrant 1 has filed all reports required to be filed by section or 15d of the. Initiate longer duration greater than 16 weeks phase 3 trial. View all regn assets, cash, debt, liabilities, shareholder equity and investments. We are very much looking forward to a successful 2017 and continuing to deliver 2016 annual report.
Financial shares highlight the share repurchase program permits the company to effect repurchases through a variety of methods, including openmarket transactions including pursuant to a trading plan adopted in accordance with rule 10b51 of the exchange act, privately negotiated transactions, accelerated share repurchases, block. Also, in december 2019, sanofi and regeneron announced their. Every second, two people celebrate their 60th birthday. In fact, the 2015 harvest came up just short of the record 2014 crop, which surpassed 20s record by a wide margin. Regeneron or the company have been prepared in accordance with the instructions to. Sanofi and regeneron present results from pivotal phase 3 study of sarilumab at american college of rheumatology annual meeting download the pdf version 20151106 mmmm dd yyyy.
Regn free report is scheduled to release fourthquarter 2015 financial results before the opening bell on feb 9, 2016. These reports include company annual reports 10k, 10q, news updates 8k, investor. Ida annual report information documents categories. Regeneron pharmaceuticals inc regn 10k annual reports. Analyze up to 10 years of full 10k annual reports and quarterly 10q sec filings for regeneron pharmaceuticals inc regn using our online tools. Regeneron reports fourth quarter and full year 2015 financial and operating. Click the button below to request a report when hardcopies become available. Regeneron will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2015 financial and operating results on tuesday, february 9, 2016, at 8. The society is a champion for science, dedicated to expanding. Get sec filings for regeneron pharmaceuticals inc regn, including annual report 10k and quarterly report 10q.
Paris and tarrytown, new york july 28, 2015 sanofi and regeneron pharmaceuticals, inc. As a convenience, provided below are selected public reports that may be of general interest to our investment community. Regeneron pharmaceuticals regn investor presentation slideshow. Business this annual report on form 10k contains forwardlooking statements that involve risks and uncertainties relating to future events and the future financial performance of regeneron pharmaceuticals, inc. Until 2019 the companys annual revenues increased up to nearly eight billion dollars. See independent assurance report on page 148 reporting scope and boundaries our financial and nonfinancial reporting consists of the annual report, the finance report and the online report. In 2017, we continue to enroll patients in our ongoing phase 3 study of eylea in nonproliferative diabetic retinopathy, a common eye disease that impacts many people with diabetes.
1104 946 1303 194 1250 708 140 300 171 460 10 1117 975 1429 1441 857 919 231 1046 1002 807 350 1373 17 1050 134 752 196 1145 839 1423 624 411 1474 1486 1103 429 820 872 171